Ocugen gets provisional approval in Bahamas for RP gene therapy OCU400
Go back to Ocugen gets provisional approval in Bahamas for RP gene therapy OCU400| (NASDAQ: OCGN) | Delayed: 1.04 +0.02 (1.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.02 | 52 Week High | $ | |||
| Open | $1.03 | 52 Week Low | $ | |||
| Day High | $1.05 | P/E | N/A | |||
| Day Low | $1.00 | EPS | $ | |||
| Volume | 3,789,922 | |||||
